Core Points - The Shenzhen-Hong Kong Stock Connect Medical Index (983036) closed at 4327.65 points, down 0.28%, with a trading volume of HKD 7.682 billion and a turnover rate of 0.9% [1] - Among the index constituents, 21 stocks rose while 36 stocks fell, with Kewei Medical leading the gainers at a 4.14% increase and Xianjian Technology leading the decliners at a 9.14% decrease [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Stock Connect Medical Index include: - Mindray Medical (sz300760) with a weight of 14.56%, latest price at HKD 198.00, and a market cap of HKD 240.063 billion, down 0.36% [1] - Yier Eye Hospital (sz300015) with a weight of 11.62%, latest price at HKD 11.23, and a market cap of HKD 104.724 billion, down 0.62% [1] - Lejin Medical (sz300003) with a weight of 4.85%, latest price at HKD 15.64, and a market cap of HKD 28.831 billion, down 0.64% [1] - Aimeike (sz300896) with a weight of 4.80%, latest price at HKD 143.25, and a market cap of HKD 43.346 billion, up 1.47% [1] - Yuyue Medical (sz002223) with a weight of 4.66%, latest price at HKD 35.68, and a market cap of HKD 35.768 billion, up 0.17% [1] - Yingke Medical (sz300677) with a weight of 3.64%, latest price at HKD 41.76, and a market cap of HKD 27.360 billion, down 0.17% [1] - Furuijia (sz300049) with a weight of 3.59%, latest price at HKD 69.33, and a market cap of HKD 18.371 billion, down 0.82% [1] - Meinian Health (sz002044) with a weight of 3.58%, latest price at HKD 5.09, and a market cap of HKD 19.924 billion, up 0.39% [1] - Sinopharm Holdings (hk01099) with a weight of 3.35%, latest price at HKD 18.15, and a market cap of HKD 56.638 billion, down 0.40% [1] - Ping An Good Doctor (hk01833) with a weight of 2.63%, latest price at HKD 12.23, and a market cap of HKD 26.434 billion, down 3.24% [1] Capital Flow Analysis - The index constituents experienced a net outflow of HKD 382 million from institutional investors, while retail investors saw a net inflow of HKD 329 million [1] - Notable individual stock capital flows include: - Meinian Health (sz002044) with a net inflow of HKD 23.6308 million from institutional investors [2] - Aimeike (sz300896) with a net inflow of HKD 5.8353 million from institutional investors [2] - Yier Eye Hospital (sz300015) with a net outflow of HKD 20.7620 million from retail investors [2]

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., specializes in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, with a significant portion of its revenue coming from overseas due to the depreciation of the RMB [3][4]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and went public on January 22, 2025. It is recognized as a national key high-tech enterprise [7]. - The company's main business segments include medical ultrasound (71.16% of revenue), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and other supplementary products (1.26%) [7]. Financial Performance - For the period from January to September 2025, the company reported a revenue of 254 million yuan, a year-on-year decrease of 2.90%, and a net profit attributable to shareholders of 88.94 million yuan, down 3.66% year-on-year [8]. - As of September 30, 2025, the company's overseas revenue accounted for 55.26% of total revenue, benefiting from the depreciation of the RMB [3]. Market Activity - On December 10, the company's stock price increased by 0.09%, with a trading volume of 17.43 million yuan and a turnover rate of 1.35%, resulting in a total market capitalization of 9.517 billion yuan [1]. - The stock has shown no significant trend in major capital inflows, with a net outflow of 1.4365 million yuan on the same day [4][5]. Shareholder Structure - As of September 30, 2025, the company had 17,000 shareholders, a decrease of 23.90% from the previous period, with an average of 3,438 shares held per shareholder, an increase of 39.99% [7]. - The largest shareholder is Huabao Zhongzheng Medical ETF, holding 1.5245 million shares, which decreased by 388,200 shares compared to the previous period [9].

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Chao Yan Co., Ltd., particularly in the medical device industry, where it has a high PE ratio compared to industry averages [1][2] - As of November 24, Chao Yan Co., Ltd. closed at 22.9 yuan, with a PE ratio of 68.98 times, and a total market capitalization of 9.809 billion yuan [1] - The company experienced a net outflow of 1.1232 million yuan in principal funds on November 24, with a total outflow of 17.8707 million yuan over the past five days [1] Group 2 - Chao Yan Co., Ltd. specializes in the research, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, with key products including medical ultrasound imaging devices and portable DR [1] - The latest financial results for the third quarter of 2025 show that the company achieved an operating income of 254 million yuan, a year-on-year decrease of 2.90%, and a net profit of 88.9445 million yuan, down 3.66% year-on-year, with a gross profit margin of 73.20% [1] - In terms of industry comparison, the average PE ratio for the medical device sector is 52.19 times, with a median of 40.14 times, positioning Chao Yan Co., Ltd. at 101st in the industry ranking [1][2]

Core Insights - Chao Yan Co., Ltd. experienced a stock price increase of 1.45% on November 12, with a trading volume of 87.1 million yuan [1] - The company reported a financing net purchase of 1.34 million yuan on the same day, with a total financing and securities balance of 92.95 million yuan [1] - As of September 30, 2025, the company recorded a revenue of 254 million yuan, a year-on-year decrease of 2.9%, and a net profit of 88.94 million yuan, down 3.66% year-on-year [2] Financing and Trading Data - On November 12, Chao Yan Co., Ltd. had a financing buy amount of 8.22 million yuan and a financing repayment of 6.89 million yuan, resulting in a net financing purchase of 1.34 million yuan [1] - The current financing balance is 92.72 million yuan, accounting for 6.30% of the circulating market value [1] - The company had a securities lending balance of 22.96 thousand yuan, with a remaining amount of 9,100 shares [1] Shareholder and Institutional Holdings - As of September 30, 2025, the number of shareholders decreased by 23.9% to 17,000, while the average circulating shares per person increased by 39.99% to 3,438 shares [2] - The largest circulating shareholder is Huabao Zhongzheng Medical ETF, holding 1.52 million shares, a decrease of 388,200 shares from the previous period [3] - New institutional shareholders include Yuanxin Yongfeng Medical Health A, holding 650,100 shares, and Medical Device ETF, holding 350,100 shares [3] Business Overview - Chao Yan Co., Ltd. specializes in the research, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, recognized as a national key high-tech enterprise [1] - The company's revenue composition includes 71.16% from medical ultrasound, 17.30% from industrial ultrasound, 5.72% from accessories, 4.56% from X-ray, and 1.26% from other sources [1]

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., specializes in the research, production, and sales of medical imaging and industrial non-destructive testing equipment, with a significant portion of its revenue coming from overseas due to the depreciation of the RMB [3][4]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and was listed on January 22, 2025. It is recognized as a national key high-tech enterprise [7]. - The company's main business segments include medical ultrasound (71.16% of revenue), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and other (1.26%) [7]. Financial Performance - For the period from January to September 2025, the company reported a revenue of 254 million yuan, a year-on-year decrease of 2.90%, and a net profit attributable to shareholders of 88.94 million yuan, down 3.66% year-on-year [8][9]. - As of September 30, 2025, the company had a total market capitalization of 10.623 billion yuan [1]. Market Dynamics - The company benefits from trends in the pet economy, medical devices, and water conservancy, as well as the depreciation of the RMB, which has positively impacted its overseas revenue, accounting for 55.26% of total revenue [3][4]. - The stock has experienced a recent increase in trading activity, with a turnover rate of 2.32% and a trading volume of 33.54 million yuan on November 6 [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 23.90% to 17,000, while the average number of circulating shares per person increased by 39.99% to 3,438 shares [7]. - The largest shareholder is Huabao Zhongzheng Medical ETF, holding 1.5245 million shares, which represents a decrease of 388,200 shares compared to the previous period [9].

Core Insights - On November 3, Chao Yan Co., Ltd. saw a stock increase of 1.14% with a trading volume of 46.31 million yuan [1] - The company reported a financing buy-in of 6.08 million yuan and a net financing buy of 2.97 million yuan on the same day [1] - As of November 3, the total financing and securities lending balance for Chao Yan Co. was 93.82 million yuan [1] Financial Performance - For the period from January to September 2025, Chao Yan Co. achieved a revenue of 254 million yuan, a year-on-year decrease of 2.90% [2] - The net profit attributable to shareholders for the same period was 88.94 million yuan, reflecting a year-on-year decline of 3.66% [2] - Cumulative cash dividends paid by the company since its A-share listing amounted to 43.69 million yuan [2] Shareholder Structure - As of September 30, 2025, the number of shareholders for Chao Yan Co. was 17,000, a decrease of 23.90% from the previous period [2] - The largest circulating shareholder is Huabao Zhongzheng Medical ETF, holding 1.52 million shares, down by 388,200 shares from the previous period [3] - New institutional shareholders include Yuanxin Yongfeng Medical Health A, holding 650,100 shares [3]

Core Insights - ChaoYan Co., Ltd. is a national high-tech enterprise specializing in medical imaging and industrial non-destructive testing equipment, with a competitive market position [1] Group 1: Business Performance - For Q3 2025, ChaoYan reported revenue of 254 million yuan, ranking 34th among 42 companies in the industry, while the industry leader, Mindray Medical, achieved revenue of 25.834 billion yuan [2] - The company's net profit for the same period was 88.9445 million yuan, ranking 19th in the industry, with the top performer, Mindray Medical, reporting a net profit of 7.814 billion yuan [2] Group 2: Financial Ratios - ChaoYan's debt-to-asset ratio was 7.85% in Q3 2025, down from 12.84% year-on-year, significantly lower than the industry average of 27.21%, indicating strong solvency [3] - The company's gross profit margin was 73.20%, an increase from 71.36% year-on-year, and higher than the industry average of 48.67%, reflecting robust profitability [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 23.90% to 17,000, while the average number of circulating A-shares held per shareholder increased by 39.99% to 3,438.65 [5] - The largest circulating shareholder, HuaBao ZhongZheng Medical ETF, held 1.5245 million shares, a decrease of 388,200 shares from the previous period [5]

Core Viewpoint - The company, Shantou Ultrasound Instrument Research Institute Co., Ltd., is experiencing fluctuations in stock performance and is involved in the medical imaging and industrial non-destructive testing equipment sectors, with a significant portion of its revenue coming from overseas due to the depreciation of the RMB [2][3]. Company Overview - Shantou Ultrasound Instrument Research Institute Co., Ltd. was established on November 15, 1982, and went public on January 22, 2025. The company specializes in the research, development, production, and sales of medical imaging and industrial non-destructive testing equipment [7]. - The company's main business revenue composition includes: medical ultrasound (71.16%), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and others (1.26%) [7]. Financial Performance - For the period from January to September 2025, the company reported a revenue of 254 million yuan, a year-on-year decrease of 2.90%, and a net profit attributable to shareholders of 88.94 million yuan, down 3.66% year-on-year [8]. - As of September 30, 2025, the company had a total of 17,000 shareholders, a decrease of 23.90% from the previous period, with an average of 3,438 circulating shares per person, an increase of 39.99% [8]. Market Activity - On October 30, the company's stock price fell by 3.20%, with a trading volume of 79.15 million yuan and a turnover rate of 5.57%, resulting in a total market capitalization of 10.366 billion yuan [1]. - The main capital inflow for the day was negative at 13.40 million yuan, indicating a trend of capital reduction over the past three days [4]. Institutional Holdings - As of September 30, 2025, the largest circulating shareholder was Huabao Zhongzheng Medical ETF, holding 1.5245 million shares, a decrease of 388,200 shares from the previous period. Other notable shareholders include Yuanxin Yongfeng Medical Health A and Hong Kong Central Clearing Limited [9].

公司董事吴宏豪先生就上述情况作出书面说明如下：公司于 2025 年 8 月 26 日、 2025 年 10 月 28 日召开第二届董事会第九次会议、第二届董事会第十次会 议，本人因公务原因，连续两次未能亲自出席董事会会议，已委托董事周宏策先 生代表本人出席上述会议，本人对上述董事会会议作出的决议均无异议。 特此公告。 证券代码：301602 证券简称：超研股份 公告编号：2025-051 汕头市超声仪器研究所股份有限公司 关于董事连续两次未亲自出席董事会会议的说明 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 汕头市超声仪器研究所股份有限公司（以下简称"公司"）分别于 2025 年 8 月 26 日、 2025 年 10 月 28 日召开了第二届董事会第九次会议、第二届董事会 第十次会议，公司董事吴宏豪先生因公务原因连续两次未亲自出席上述董事会会 议，委托董事周宏策先生出席并表决。 根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作（2025 年修订）》第 3.3.4 规定"连续两次未亲自出席董事会会议，董 事应当作出书面说明并对 ...

Core Viewpoint - The company, Chaoyan Co., Ltd., has experienced a decline in stock performance and financial metrics, indicating potential challenges in its operational performance and market position [1][2]. Financial Performance - As of September 30, 2025, Chaoyan Co., Ltd. reported a revenue of 254 million yuan, a year-on-year decrease of 2.90% [2]. - The net profit attributable to shareholders for the same period was approximately 88.94 million yuan, reflecting a decline of 3.66% year-on-year [2]. - Cumulative cash dividends distributed since the company's A-share listing amount to approximately 43.69 million yuan [2]. Stock and Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 23.90% to 17,000, while the average number of circulating shares per shareholder increased by 39.99% to 3,438 shares [2]. - The total financing balance for Chaoyan Co., Ltd. is approximately 96.65 million yuan, accounting for 6.63% of its market capitalization [1]. Institutional Holdings - The largest circulating shareholder is Huabao Zhongzheng Medical ETF, holding 1.5245 million shares, which decreased by 388,200 shares compared to the previous period [3]. - New institutional shareholders include Yuanxin Yongfeng Medical Health A, holding 650,100 shares, and Medical Device ETF, holding 350,100 shares [3]. - Other notable changes include Hong Kong Central Clearing Limited increasing its holdings by 62,000 shares to 532,000 shares [3].